辉瑞CEO称“全力以赴”开发实验性减肥药

金融界
14 Jan

美国制药商辉瑞公司首席执行官Albert Bourla周一在摩根大通医疗保健会议上表示,该公司正“全力以赴”开发其实验性减肥药,并一直在招募该领域的更多专家。Bourla表示,这些专家正在帮助辉瑞做出更好、更合理的决策,该公司可能会在今年下半年开始对其GLP-1R小分子激动剂Danuglipron进行后期研究。经过大量实验后,辉瑞预计将在几个月内获得剂量测试研究的数据。通过这款药物,辉瑞公司旨在为患者提供一种更方便的、替代注射剂的口服药物——目前这两种药物在减肥治疗市场上占据主导地位。

责任编辑:山上

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10